In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on Ocugen (OCGN – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $0.70.
According to TipRanks, LeBoyer is an analyst with an average return of -1.4% and a 30.81% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as MAIA Biotechnology, Inc., Onconova Therapeutics, and Tonix Pharma.
Currently, the analyst consensus on Ocugen is a Strong Buy with an average price target of $4.25, implying a 507.14% upside from current levels. In a report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $4.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.11 and a one-year low of $0.67. Currently, Ocugen has an average volume of 6.32M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Read More on OCGN:
- Ocugen Provides Business Update with First Quarter 2023 Financial Results
- OCGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
- Ocugen announces FDA granted ODD for OCU410ST
- Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
